Navigation Links
FierceBiotech Names iPierian as One of the 'Fierce 15' Biotech Companies of 2010
Date:9/15/2010

SOUTH SAN FRANCISCO, Calif., Sept. 15 /PRNewswire/ -- iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced that FierceBiotech has named iPierian  as one of 2010's Fierce 15, designating it as one of the most promising biotech companies in the industry. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position.

"iPierian's scientific advisory board is a Who's Who of stem cell and top disease experts," said John Carroll, editor of FierceBiotech. "By applying cutting-edge work on cell reprogramming and differentiation, iPierian promises to pioneer iPS technology that can offer a radically improved approach to identifying and developing new therapies for some of the world's toughest disease targets, where there are only poor in vivo and in vitro models available."

"Following our 2009 'Fierce 15' award, we are delighted that the editors of FierceBiotech selected iPierian for this recognition again in 2010," said Michael C. Venuti, PhD, CEO of iPierian.  "With our focus on industrializing and applying this transformative technology to drug discovery and development, we look forward to advancing our proprietary therapeutic programs, and to entering collaborative arrangements with pharmaceutical companies and foundations over the coming year."

About iPierian

iPierian is the leading biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and directed differentiation of patient cells for the discovery and development of new therapeutics. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success by using precise human disease models to develop proprietary small molecule or biologic therapeutics. The initial therapeutic focus of the company is neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease, in addition to a broad therapeutic area program intended for partnering in metabolic disease.

The company's Scientific Advisory Board (SAB) is comprised of leading researchers and authorities in the stem cell field, including individual investigators from the Harvard Stem Cell Institute, The Gladstone Institute and The University of California, San Francisco.  Our scientific founders are George Q. Daley, M.D., Ph.D., Douglas A. Melton, Ph.D., and Lee L. Rubin, Ph.D. all of the Harvard Stem Cell Institute, and Deepak Srivastava, M.D., of the Gladstone Institute and UCSF.

iPierian is located in South San Francisco, California. For more information, please visit www.ipierian.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at http://www.fiercebiotech.com.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
2. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
3. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
4. Signum Biosciences Names Braham Shroot as Chief Executive Officer
5. Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation
6. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
7. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
8. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
9. Thomson Reuters Names the Worlds Hottest Researchers
10. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
11. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
(Date:3/22/2017)... 22, 2017   VWR (NASDAQ: ... product and service solutions to laboratory and ... acquired EPL Archives, Inc., an international biorepository ... entire regulated product research, development and commercialization ... and ancillary services. EPL Archives is widely ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical for ... increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is a ... , To meet this demand, the team at SCIEX has developed a ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has ... Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in Boston, ... for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer ...
Breaking Biology Technology:
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):